WALVAX(SZ:300142) Xin Lang Cai Jing·2025-08-28 07:23Company Overview - Watson Bio, established on January 16, 2001, is located in Kunming, Yunnan Province, and was listed on November 12, 2010. The company specializes in the research, production, and sales of vaccine products [1] - The revenue composition of Watson Bio includes: non-immunization planning vaccines 85.19%, technical services 7.13%, immunization planning vaccines 4.91%, intermediate products 2.14%, and others 0.63% [1] Stock Performance - On August 28, Watson Bio's stock price fell by 0.62%, closing at 12.75 yuan per share, with a trading volume of 791 million yuan and a turnover rate of 4.03%. The total market capitalization is 20.392 billion yuan [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 5.27% during this period [1] Fund Holdings - According to data from the top ten holdings of funds, one fund under Penghua Fund has a significant position in Watson Bio. The Biovaccine ETF (159657) increased its holdings by 10,400 shares in the second quarter, bringing the total to 659,900 shares, which accounts for 6.28% of the fund's net value, ranking as the fifth-largest holding [2] - The Biovaccine ETF (159657) was established on February 22, 2023, with a current size of 116 million yuan. Year-to-date returns are 12.56%, ranking 3081 out of 4222 in its category, while the one-year return is 28.8%, ranking 2952 out of 3776. Since inception, the fund has experienced a loss of 27.96% [2] Fund Manager Information - The fund manager of the Biovaccine ETF (159657) is Lin Song, who has been in the position for 2 years and 61 days. The total asset size of the fund is 1.316 billion yuan, with the best return during the tenure being 26.49% and the worst return being -12.68% [3]